ArticleFrontiers in cellular and infection microbiology2016
Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles.
Article in Frontiers in cellular and infection microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Prefusion-stabilized Hantaan virus glycoprotein nucleic acid vaccine elicits potent neutralizing antibody responses via germinal center activation.Nature communications · 2026Article
- A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus.NPJ vaccines · 2024Article
- Genomic sequencing revealed recombination event between clade 1 and clade 2 occurs in circulating varicella-zoster virus in China.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus.NPJ vaccines · 2024Article
- Disparate macrophage responses are linked to infection outcome of Hantan virus in humans or rodents.Nature communications · 2024Article
- Investigation of a subunit protein vaccine for HFRS based on a consensus sequence between envelope glycoproteins of HTNV and SEOV.Virus research · 2023Article
- Construction of a Hantaan Virus Phage Antibody Library and Screening for Potential Neutralizing Activity.Viruses · 2023Article
- Hemorrhagic Fever with Renal Syndrome in Asia: History, Pathogenesis, Diagnosis, Treatment, and Prevention.Viruses · 2023Review
- Evaluation of porcine GM-CSF during PRRSV infectionFrontiers in immunology · 2022Article
- Dihydropyridine-derived calcium channel blocker as a promising anti-hantavirus entry inhibitor.Frontiers in pharmacology · 2022Article
- Utilizing image and caption information for biomedical document classification.Bioinformatics (Oxford, England) · 2021Article
- Vaccines and Therapeutics Against Hantaviruses.Frontiers in microbiology · 2019Review
- Interference of retroviral envelope with vaccine-induced CD8Retrovirology · 2017Article
- In-Cell Western Assays to Evaluate Hantaan Virus Replication as a Novel Approach to Screen Antiviral Molecules and Detect Neutralizing Antibody Titers.Frontiers in cellular and infection microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A safe and effective Hantaan virus (HTNV) vaccine is highly desirable because HTNV causes an acute and often fatal disease (hemorrhagic fever with renal syndrome, HFRS). Since the immunity of the inactivated vaccine is weak and the safety is poor, HTNV virus-like particles (VLPs) offer an attractive and safe alternative. These particles lack the viral genome but are perceived by the immune system as virus particles. We hypothesized that adding immunostimulatory signals to VLPs would enhance their efficacy. To accomplish this enhancement, we generated chimeric HTNV VLPs containing glycosylphosphatidylinositol (GPI)-anchored granulocyte macrophage colony-stimulating factor (GM-CSF) or CD40 ligand (CD40L) and investigated their biological activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.